Blood · 2011
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.
Оценочное исследованиеСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПоддержка правительства СШАПоддержка службы здравоохранения СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arora Mukta, Klein John P, Weisdorf Daniel J, Hassebroek Anna, Flowers Mary E D, Cutler Corey S, Urbano-Ispizua Alvaro, Antin Joseph H, Bolwell Brian J, Boyiadzis Michael, Cahn Jean-Yves, Cairo Mitchell S, Isola Luis, Jacobsohn David A, Jagasia Madan, Klumpp Thomas R, Lee Stephanie J, Petersdorf Effie W, Santarone Stella, Gale Robert Peter, Schouten Harry C, Spellman Stephen, Wingard John R, Horowitz Mary M, Pavletic Steven Z
Аннотация
Several risk factors are associated with increased mortality in patients with chronic graft-versus-host disease (cGVHD), but there is considerable variability in the reported factors. Therefore, we evaluated patient, transplantation, and cGVHD characteristics to develop a risk score in 5343 patients with cGVHD. Ten variables were identified as being significant in multivariate analysis of overall survival and nonrelapse mortality (NRM): age, prior acute GVHD, time from transplantation to cGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score, and platelet count. These 10 variables were used to build a cGVHD risk score, and 6 risk groups (RGs) were identified. The 5-year NRM was 5% (1%-9%) in RG1, 20% (19%-23%) in RG2, 33% (29%-37%) in RG3, 43% (40%-46%) in RG4, 63% (53%-74%) in RG5, and 72% (59%-85%) in RG6. The 5-year overall survival was highest at 91% (95% confidence interval [CI]:85%-97%) in RG1, followed by 67% (65%-69%) in RG2, 51% (46%-55%) in RG3, 40% (37%-43%) in RG4, 21% (12%-30%) in RG5, and 4% (0%-9%) in RG6 (all P < .01). This analysis demonstrates the usefulness of data from a large registry to develop risk-score categories for major transplantation outcomes. Validation of this cGVHD risk score is needed in a different population to ensure its broad applicability.
Предметные рубрики MeSH
AdolescentAdultAgedBiomedical ResearchBlood TransfusionChildChild, PreschoolChronic DiseaseCohort StudiesFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansInfantInternational AgenciesMaleMiddle AgedMulticenter Studies as TopicRegistriesResearch DesignRisk FactorsSeverity of Illness IndexSurvival AnalysisYoung Adult